Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EDAP 
EDAP TMS SA (EDAP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: EDAP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.77
1 Year Target Price $5.77
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.67% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 90.11M USD | Price to earnings Ratio - | 1Y Target Price 5.77 |
Price to earnings Ratio - | 1Y Target Price 5.77 | ||
Volume (30-day avg) 3 | Beta -0.2 | 52 Weeks Range 1.21 - 3.18 | Updated Date 09/16/2025 |
52 Weeks Range 1.21 - 3.18 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-28 | When - | Estimate -0.1602 | Actual -0.15 |
Profitability
Profit Margin -33.35% | Operating Margin (TTM) -35.95% |
Management Effectiveness
Return on Assets (TTM) -17.72% | Return on Equity (TTM) -55.7% |
Valuation
Trailing PE - | Forward PE 38.02 | Enterprise Value 83036865 | Price to Sales(TTM) 1.43 |
Enterprise Value 83036865 | Price to Sales(TTM) 1.43 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA 1165.78 | Shares Outstanding 37392100 | Shares Floating 29032180 |
Shares Outstanding 37392100 | Shares Floating 29032180 | ||
Percent Insiders - | Percent Institutions 37.83 |
Upturn AI SWOT
EDAP TMS SA
Company Overview
History and Background
EDAP TMS SA, founded in 1979, is a global medical technology company focused on minimally invasive medical devices for urology. Initially focused on extracorporeal shockwave lithotripsy (ESWL), it has expanded into High-Intensity Focused Ultrasound (HIFU) for prostate cancer treatment.
Core Business Areas
- HIFU (High-Intensity Focused Ultrasound): Develops and markets HIFU devices for non-invasive prostate cancer treatment using focused ultrasound energy.
- Extracorporeal Shockwave Lithotripsy (ESWL): Provides ESWL systems for treating kidney stones. Though a mature business, it still generates revenue.
- Distribution: EDAP distributes devices from strategic partner companies focusing on various urological ailments, but also on robotic assistance in order to facilitate operations.
Leadership and Structure
The company is led by Marc Oczachowski as Chairman and CEO. The organizational structure includes departments for R&D, Sales & Marketing, Manufacturing, and Regulatory Affairs.
Top Products and Market Share
Key Offerings
- Focal One HIFU: A robotic HIFU system for targeted prostate cancer ablation. While market share data is difficult to pinpoint precisely, EDAP is a significant player in the HIFU market. Competitors include Profound Medical (PROF) with TULSA-PRO and Sonacare Medical.
- Sonolith i-sys: A modular ESWL system for kidney stone treatment. The ESWL market is relatively mature. Competitors include Siemens Healthineers and Dornier MedTech.
- ExactVu Micro-Ultrasound: A micro-ultrasound system for prostate biopsy guidance through our strategic partnership with Exact Imaging. The market share in this space is growing. Competitors include BK Medical (now owned by GE Healthcare).
Market Dynamics
Industry Overview
The medical device industry, particularly in urology, is characterized by technological advancements, increasing demand for minimally invasive procedures, and stringent regulatory requirements.
Positioning
EDAP TMS SA positions itself as a leader in minimally invasive urological solutions, particularly in prostate cancer treatment with HIFU. Its competitive advantage lies in its patented HIFU technology and robotic precision.
Total Addressable Market (TAM)
The TAM for prostate cancer treatment is estimated to be in the billions of dollars globally. EDAP is positioned to capture a portion of this market with its HIFU technology, estimated to be around 4% of the TAM based on their revenue
Upturn SWOT Analysis
Strengths
- Proprietary HIFU Technology
- Robotic Precision
- Minimally Invasive Procedures
- Established Market Presence in HIFU
Weaknesses
- Limited Product Portfolio
- Dependence on HIFU Market
- Smaller Scale Compared to Larger Competitors
- Geographic Concentration of Sales
Opportunities
- Expansion into New Markets (e.g., Asia)
- Development of New HIFU Applications
- Partnerships and Acquisitions
- Increasing Awareness of HIFU Benefits
Threats
- Competition from Established Medical Device Companies
- Technological Disruption
- Reimbursement Challenges
- Regulatory Changes
Competitors and Market Share
Key Competitors
- PROF
- BK Medical (Owned by GE)
- SIEMENS HEALTHINEERS (SMMNY)
Competitive Landscape
EDAP TMS SA faces competition from larger, more established medical device companies, as well as smaller, specialized players. Its competitive advantage lies in its HIFU technology and robotic precision, but it needs to continue to innovate and expand its product portfolio to maintain its position.
Growth Trajectory and Initiatives
Historical Growth: EDAP TMS SA has experienced growth in recent years, driven primarily by increased adoption of HIFU technology.
Future Projections: Analyst projections suggest continued growth for EDAP TMS SA, driven by expansion of HIFU into new markets and applications.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts in Asia, developing new HIFU applications, and pursuing strategic partnerships.
Summary
EDAP TMS SA is a growing medical technology company specializing in minimally invasive urological solutions, particularly HIFU for prostate cancer treatment. The company's proprietary technology and robotic precision give it a competitive edge in the HIFU market. However, EDAP faces challenges from larger competitors and needs to diversify its product portfolio. Its growth trajectory relies on expanding into new markets and developing new HIFU applications.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EDAP TMS SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1997-07-31 | CEO & Director Mr. Ryan Rhodes | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 310 | Website https://focalone.com |
Full time employees 310 | Website https://focalone.com | ||
EDAP TMS S.A., together with its subsidiaries, develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing and sales channels, as well as through third-party distributors and agents. The company serves academic, public, and private hospitals as well as urology clinics. EDAP TMS S.A. was incorporated in 1979 and is based in Vaulx-en-Velin, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.